Doc code IDS

PTO/SB/08a (03-08)
Approved for use through 06/30/2008 OMB 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Doc description: Information Disclosure Statement (IDS) Filed Under the Paperwork Reduction Act of 1995, no persons are required to respo nd to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURI
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

nanian

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1	5124441		2008-06-23	Pharmacia Aktiebolag			
	2	6727251		2004-04-27	Vertex Pharmaceuticals Incorporated			
If you wisl	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1	20030207873		2003-11-06	Harrington et al.			
	2	20030144309		2003-07-31	Choon-Moon			
E I'	3	20040009996		2004-15-01	Moon et al.			
	4	20030171389		2003-09-11	Bernis et al.			

U.S. PATENTS

Application Number		10632340
Filing Date		2003-08-01
First Named Inventor Come		elia J. Forster
Art Unit		1624
Examiner Name Venka		ataraman Balasubramanian
Attornou Docket Number		VIDIN2 110 LIC

	5	20040029857		2004-02-12		Hale et al.					
	6	20050234059		2005-10	1-20	Hale et al.					
	7	20040097531		2004-05	i-20	Ledeboer et al	-				
	8	20030096813		2003-05-22		Cao et al.					
	9	20030004161		2003-01-02		Vertex Pharma Incorporated	aceuticals				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor	n. Add		
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³		Country Kind Code4			Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	T4
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button			
			NO	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or of	nal, seri	al, symp	osium,	catalog, etc), o					T5
	Charpiot, B. et al., "Quanacolines: Combined type 3 and 4 phosphodiesterase inhibitors", Bioorg. Med. Chem. Lett., 8 (20), 2891-2898 (1999).										

Application Number		10632340
Filing Date		2003-08-01
First Named Inventor Come		elia J. Forster
Art Unit		1624
Examiner Name Venka		ataraman Bal'asubramanian
Attorney Docket Number		VPI/02-119 US

2	Shikmanev, K.S. et al., "Heterocyclization of quinazor-2-yiguanidines. 1. Reaction with amino acids", Chem. Heterocycl. Compd., 35 (7), 818-820 (1999).	
3	Singh, S.P. et al., "Synthesis & Mass Spectra of Some Substituted 2-(2"-Benzazolylamino/pyrimidines", Indian J. Chem. Sect. B, 22(1), 37-42 (1983).	
4	Ti, J. et al., "Anticandidal activity of pyrimidine-peptide conjugates", J. Med. Chem., 23(8), 913 – 918 (1980).	
5	Kretzschmar, E. et al., "Synthese von 2,6-disubstituerten 4-Hydroxy-5,6,7,8-tetrahydropyrido(4,3-d)pyrimidinen", Pharmaze, 43(7), 475-476 (1998).	
6	Norman, M.H. et al., "Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists", J. Med. Chem., 43(22), 4288–4312 (2000).	
7	Nugent, R.A. et al., "Pyrimdine Thioethers: A Novel Class of HIV-1 Reverse Transcriptase Inhibitors with Activity Against BHAP-Resistant HIV", J. Med. Chem., 41, 3793-3803 (1988).	
8	Myers, M.R. et al., "The synthesis and SAR of new 4-(N-ally/14-pheny/jamino-6,7-dimethoxyou/nazolines and 4-(N-ally/14-pheny/jaminopyrazolo)54-dipyrimidines, mitablos of CSF-fit tyrosine kinese activity", Bloorg, Med. Chem.	
9	Agarwal, N. et al., "Suitably functionalised pyrimidines as potential antimycotic agents", Bioorg. Med. Chem. Lett., 10, 8, 703-706 (2000).	
10	Crespo, M.I. et al., "Design, Synthesis, and Biological Activities of New Thiono[3,2-d]pyrmidines as Selective Type 4 Phosphodiesterase Inhibitors", J. Med. Chem., 41 (21), 4021-4035 (1998).	
11	Noell, C.W. et al., "Potenbal Punne Anlagonists. XX. The Preparation and Reactions of Some Methylthiopurines", J. Am. Chem. Soc., 81(22), 5997 – 6007 (1959).	
12	Lubbers, T. et al., "Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase nihibitors", Bioorg Med. Chem. Lett., 10, 8, 821-826 (2000).	

Ī	Application Number		10632340		
	Filing Date		2003-08-01		
	First Named Inventor Come		elia J. Forster		
	Art Unit		1624		
	Examiner Name	Venka	ataraman Balasubramanian		
	Attorney Docket Number		VPI/02-119 US		

13	D'Atri, G. et al., "Novel pyrimidine and 1,3,5-triazine hypolipemic agents", J. Med. Chem. 27(12), 1621 – 1629 (1984).	
14	Venugopalan, B. et al., "Synthesis and antimalanal activity of pyndol3.2-fiquinozalines and their oxides", Indian J. Chem. Sect. B, 34, 9, 778-790 (1995).	
15	Curd, F.H.S. et al, "Synthetic antimalarials. Part XVII. Some aminoalitylaminoquinoline derivatives", J. Chem. Soc., 898 –909 (1947).	
16	Haworth, R.D. et al., "Synthetic antimalarisis. Part XXVIII. Some derivatives of phthalazine, quinoxaline, and isoquinoline", J. Chem. Soc., 777 – 782 (1948).	
17	Nair, M.D., et al., "3-Chloroiscearbostyril & its Chlorination Products", Indian J. Chem., 467-470 (1987).	
18	Jeffery, J.E. et al., "Synthesis of sibultramine, a novel cyclobut/salkylamine useful in the treatment of obesity, and its major human metabolites", J. Chem. Soc., Perkin Trans. 1, 21, 2582-2589 (1996).	
19	Checco, D. et al., 'An Improved Preparation of 1-Methyl4-Cyano-4-phenylopendine', Org. Prep. Proced. Int., 18 (4), 478-480 (1996).	
20	Fedorynski, M. et al., "Synthesis of 1-Anycyclopropanecis/bonitriles under Phase-transfer Catalytic Conditions", Org. Prep. Proced. Int., 27(3), 355-359 (1995).	
21	Suzuki, S. et al., "Application of electrogenerated imphernylmethyl anion as a base for alkylation of anylacetic esters and anylacetonithies and somerization of allythenizenes", Can. J. Chem., 72(2): 357–361 (1994)	
22	Prasad, G. et al., "18-Crown-6 as a catalyst in the dialitylation of o-nthrophenacyl derivatives", J. Org. Chem., 25, 7188-7190 (1991).	
23	Moss, R.A. et al., "Conversion of "Obsfinate" Nitriles to Armdines by Garigpusif's Reaction", Tetrahedron Lett., 36(48), 8761-8764 (1995).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) At Unit Examina Attorner

Application Number		10632340
Filing Date		2003-08-01
First Named Inventor Come		lia J. Forster
Art Unit		1624
Examiner Name	Venka	ataraman Balasubramanian
Attorney Docket Number		VPI/02-119 US

24	Gargipati, R.S., "An efficient conversion of nitriles to amidines", Tetrahedron Lett., 31(14), 1969-1972 (1990).	
25	Warner, S.L. et al. "Targeting Autora-2 Kinase in Cancer," Mol. Cancer Thera., 2, 589-585, 2003.	
26	Wagman, A.S. et all, "Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes," Current Pharmaceutical Design, 10, 1105-1137 (2004).	
27	Nezu, Y. et al., "Dimethoxypyrimidnes as Novel Herboides. Part 2. Synthesis and Herboidel Activity of Dimethoxyphenoxypyrimidnes and Analogues," Pestic. Sci., 47: 115-124 (1996).	
28	Tanaka, T.U. et al., "Evidence that the lpft-Ski15 (Aurora Kinase-INCENP) Complex Promotes Chromosome 8i- orientation by Altering Kinebochore-Spindle Pole Connections," Cell, 108, 317-329 (2002).	
29	Scriano, P. et al., "Targeted Disruption of the C-SIC Pmto-Oncogene Leads to Osteopetrosis in Mice," Cell, 64: 683-702, (1991).	
30	Campbell, S.F. et al., "2.4-Diamino-6.7-dimethoxyquinazolines. 3.2-(4-Helerocydylpiperazini-yi) Derivatives as at- Adrenoceptor Antagonists and Antihyperfensive Agents," J. Med. Chem., 30, 1794-1799 (1987).	
31	Casanova, B. et al., "Revisión critica de la patogenia actual de la esciercias múltiple y futuras direcciones posibles," Rev. Neurol., 28 (9): 909-915 (1999).	
32	Simone, J.V., "Oncology: Introduction" in Cecil Textbook in Medicine, 20th ed., Vol. 1, 1004-1010 (1996).	
33	Coleman, R.A., "The Biological Evaluation of New Compounds" in Medicinal Chemistry. Principles and Practice, King, Frank D. ed, Royal Society of Chemistry, 53-66 (1994).	
34	The CONDENSED CHEMICAL DICTIONARY, Skith Edition by Arthur and Elizabeth Rose, 38 (1961).	

Application Number		10632340			
Filing Date		2003-08-01			
First Named Inventor Come		elia J. Forster			
Art Unit		1624			
Examiner Name	Venka	ataraman Balasubramanian			
Attorney Docket Number		VPI/02-119 US			

35	Damasio, A.R., "Alzheimer's Disease and Related Dementia," in Ceol Textbook of Medicine, 20th ed., 2, 1992-1996 (1996).	
36	Rogers, E. et al., "The aurora kinese AIR-2 functions in the release of chromosome cohesion in Geenorhabdits elegans meroess," J. Cell Biol., 157(2): 219–229 (2002)	
37	Flisher A., "Therapeutic Strategies in Alchemer's Disease: M1 Muscarinic Agonists," Jpn. J. Pharmacol., 84(2):101-12 (2000).	
38	Frame, M.C., "Sirc in cancer: deregulation and consequences for cell behaviour," Biochimica et Biophysica Acta., 1602, 114–130 (2002).	
39	Frampton, J.E. et al., "Pentoxfylline (Oxpentifylline) - A Review of its Therapeutic Efficacy in the Management of Perpheral Vascular and Cerebrovascular Discreter," Drugs & Aging, 7(6): 480-503 (1996).	
40	Garnellin, C.R., "Past Approaches to Discovering New Drugs as Medicines" in Medicinal Chemistry, Principles and Practices, King, Frank D. ed, Royal Society of Chemistry, 189-205 (1994).	
41	Hamdane, M. et al., "A Therapeutic Target in Alzheimer Neurodegeneration," J. Mol. Neurosci., 19(3): 275-87 (2002).	
42	Hardt, S.E. et al., "Glycogen Synthase Kinsse-3\$ - A Novel Regulator of Cardiac Hypertrophy and Development," Circulation Research, 90: 1055-1063 (2022).	
43	Heaney, F. et al., "Pyrimidine annelated heterocycles—synthesis and cycloaddition of the first pyrimido{1,4]diazepine Noxides," J. Chem. Soc., Perkin Trans. 1, 622-632 (2001).	
44	Hendriksen, E.J. et al., "Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty raits," Am. J. Physiol. Endocrinol. Melab., 284: E892-E900 (2003).	
45	Okafor, C.O., "Studies in the Heterocyclic Senes, X. 1,3,9-Triazaphenothiazine Ring System, a New Phenothiazine Ring," J. Org. Chem., 40(19): 2753-2755 (1975).	

Application Number		10632340
Filing Date		2003-08-01
First Named Inventor Come		lia J. Forster
Art Unit		1624
Examiner Name Venka		ataraman Balasubramanian
Attorney Docket Numb	er	VPI/02-119 US

Date Considered

	46	Jambhekar, S. S., "Biopharmaceutical Properties of Drug Substances" in Principles of Medicinal Chemistry, 4th ed., 12-24, (1995).					
	47	Layzer, R.B., "Section Five - Degenerative Diseases of the Nervous System" in Cecil Textbook of Medione, 20th ed., 2. 2050-2057 (1995).					
	48	Lee, S.J. et al., "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyrdyl- and 2-Imidazolylou/mazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities," J. Med. Chem., 38 (18) 3547-3557 (1995).					
	49	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herboides. Plat 1. Synthesis and Herboidel Activity of Dimethoxyphenoxypyrimidines and Analogues," Pestic. Sci., 47: 103-113 (1996).					
	50	Cohen, P., "Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action", Blochem. Soc. Trans., 21, 555-567 (1993).					
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature